Multiple Myeloma News

ORIGINAL ARTICLE: Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

Wed, 27 Aug 2008 21:24:37 +0200

Patients with newly diagnosed multiple myeloma who were ineligible for treatment with high-dose chemotherapy plus hematopoietic stem-cell transplantation were randomly assigned to receive either melphalan and prednisone alone or melphalan and prednisone plus bortezomib. The time to disease progression (the primary outcome) was longer in the bortezomib group. The combination of bortezomib, ...

Bandwidth saved by RSScache.com

MMRC Partners With Celgene Corporation On Phase I/II Trial Of Pomalidomide In Relapsed And Refractory Multiple Myeloma ...

Tue, 26 Aug 2008 11:03:37 +0200

The Multiple Myeloma Research Consortium (MMRC) announced the initiation of a clinical trial with the oral immunomodulatory agent pomalidomide (CC-4047) in patients who have received at least two prior therapies including treatments with REVLIMID® (lenalidomide) and VELCADE® (bortezomib) for Injection.

Bandwidth saved by RSScache.com

[Ad] Oprah's Superfood of the Year!

Detoxify and Lose Weight with AcaiPure - Click Here for Free Trial

The Multiple Myeloma Research Consortium Partners with Celgene Corporation on Phase I/II Trial of Pomalidomide ...

Fri, 22 Aug 2008 20:37:46 +0200

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a clinical trial

Bandwidth saved by RSScache.com

Home Test Kit Superstore

Thu, 21 Aug 2008 08:07:30 +0200

Instant Home Tests: Variety Home and Workplace Drug Testing Kits, Tests for Cancer, HIV and AIDS, Fertility Testing Kits and more ...

Bandwidth saved by RSScache.com

MMRF, MMRC Launch Multiple Myeloma Genomics Portal

To: HEALTH EDITORS Contact: Anne Quinn Young, Program Director, of Multiple Myeloma Research Foundation, +1-203-652-0212, quinnyounga@themmrf.org NORWALK, Conn., Aug. 1 /PRNewswire-USNewswire/ - The Multiple Myeloma Research Foundation and Multiple Myeloma Research Consortium today ...

Bandwidth saved by RSScache.com

Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma

Tue, 19 Aug 2008 20:28:37 +0200

Bristol-Myers Squibb Company (NYSE: BMY) and PDL BioPharma, Inc. (NASDAQ: PDLI) today announced an agreement for the global development and commercialization of PDL BioPharma's anti-CS1 antibody, elotuzumab, previously known as HuLuc63, currently in Phase I development for multiple myeloma.

Bandwidth saved by RSScache.com

The Multiple Myeloma Research Consortium Announces Initiation Of First Four-Drug Combination Study To Treat Newly ...

Mon, 18 Aug 2008 12:13:30 +0200

The Multiple Myeloma Research Consortium (MMRC) announced the initiation of a four-drug combination study with REVLIMID® (lenalidomide), VELCADE® (bortezomib) for Injection, DOXIL® (doxorubicin HCl liposome injection) and dexamethasone for the treatment of multiple myeloma in patients who are previously untreated.

Bandwidth saved by RSScache.com

The Multiple Myeloma Research Consortium Announces Initiation of First Four-Drug Combination Study to Treat ...

Wed, 13 Aug 2008 13:51:28 +0200

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a four-drug combination study with REVLIMID(R) (lenalidomide), VELCADE(R) (bortezomib) for Injection, DOXIL(R) (doxorubicin HCl liposome injection) and dexamethasone for the treatment of multiple myeloma in patients who are previously untreated.

Bandwidth saved by RSScache.com

The Multiple Myeloma Research Consortium Announces Initiation of First Four-Drug Combination Study to Treat ...

Wed, 13 Aug 2008 13:15:00 +0200

NORWALK, Conn.-The Multiple Myeloma Research Consortium today announced the initiation of a four-drug combination study with REVLIMID® , VELCADE® for Injection, DOXIL® and dexamethasone for the treatment of multiple myeloma in patients who are previously untreated.

Bandwidth saved by RSScache.com

Clinical updates and nursing considerations for patients with multiple myeloma.

Multiple myeloma accounts for approximately 1% of all new cancers and is characterized by abnormal plasma cell proliferation in the bone marrow. As a result, many patients develop bone lesions, hypercalcemia, anemia, and renal impairment. Although no cure exists for multiple myeloma, current ...

Bandwidth saved by RSScache.com

Edward J. Phillips, Son of 'Dear Abby' and Creator of Belvedere Vodka, Donates $1 Million to Multiple Myeloma Research Consortium; Funds Allocated for Research for Uncommon Cancer of the Plasma Cell.

The Multiple Myeloma Research Consortium has received a $1 million grant from Edward J. Phillips and his wife, Leslye; Mr. Phillips is the son of the creator of the world renowned column, Dear Abby , and was diagnosed with multiple myeloma in 2003. Mr. Phillips is the Chief Executive Officer ...

Bandwidth saved by RSScache.com

The Multiple Myeloma Research Foundation Announces 2002 Research Award Recipients; $1.6 million awarded to accelerate cutting-edge multiple myeloma research.

NEW CANAAN, Conn. - The Multiple Myeloma Research Foundation , the world's largest private funder of myeloma-specific research, today announced the awarding of 20 research grants worth nearly $1.6 million through its Research Awards program. The grant programs that were funded include the ...

Bandwidth saved by RSScache.com

[Ad] “How To Lose Stomach Fat”

Finally, A Diet That Really Works! As Seen On CNN, CBS, NBC & Fox!

The Multiple Myeloma Research Foundation is Available to Provide Information About Multiple Myeloma.

Recently Diagnosed with Multiple Myeloma, New York Yankee Mel Stottlemyer is Among the 50,000 Americans who are Battling this Cancer NEW CANAAN, Conn., April 12 /PRNewswire/ - Recently, Yankee Pitching Coach, Mel Stottlemyer was diagnosed with multiple myeloma, a form of blood cancer. This sad ...

Bandwidth saved by RSScache.com

The Multiple Myeloma Research Foundation Funds More Than $8 Million in Research in 2005, Including 15 New Therapies.

NEW CANAAN, Conn., Jan. 31 /PRNewswire/ - The Multiple Myeloma Research Foundation , the world's leading private funder of multiple myeloma research, today announced that it awarded more than $8 million in research grants and funding to the Multiple Myeloma Research Consortium in ...

Bandwidth saved by RSScache.com

Multiple Myeloma

Multiple myeloma Definition Multiple myeloma is a cancer in which antibody-producing plasma cells grow in an uncontrolled and invasive manner. Description Multiple myeloma, also known as plasma cell myeloma, is the second-most common cancer of the blood. It is the most common type of ...

Bandwidth saved by RSScache.com

The role of high-dose chemotherapy supported by hematopoietic stem cell transplantation in patients with multiple myeloma: implications for nursing.

Multiple myeloma , a neoplastic proliferation of plasma cells originating from the B-cell line, is associated with deleterious complications and poor outcomes. The failure of conventional combination chemotherapies to improve the overall survival of patients with MM has led to the use of ...

Bandwidth saved by RSScache.com

Multiple myeloma

INTRODUCTION Multiple myeloma is a cancer caused by malignant plasma cells. This disease is a hematologic cancer that affects many people. There are a number of risks that are associated with multiple myeloma, although nothing strictly predisposes the disease. The number of multiple myeloma cases ...

Bandwidth saved by RSScache.com